Clinical Trials
Concurrent PLD and Dual HER2 Blockade in HER2-Positive Breast Cancer: METIS Phase 2 Trial
Zheng et alSignal Transduction and Targeted Therapy

Concerns regarding cardiotoxicity have historically restricted the concurrent administration of anthracyclines with HER2-targeted agents in the neoadjuvant setting for HER2-positive breast cancer. The randomized phase II METIS trial (NCT04172259) assessed whether a neoadjuvant regimen incorporating concurrent pegylated liposomal doxorubicin (PLD) and dual HER2 blockade with trastuzumab and pertuzumab could improve efficacy without increasing cardiac risk compared with an epirubicin and cyclophosphamide (EC)-based sequential regimen.
The study randomized 156 patients with stage II–III HER2-positive breast cancer to receive either the PLD-based concurrent regimen or the EC-based sequential regimen. Patients in the PLD-based concurrent cohort achieved a higher pathological complete response (pCR) rate of 67.5% compared with 48.7% in the EC-based sequential cohort (difference, 18.8%; 95% confidence interval [CI], 3.6–34.0; P = 0.033). Subgroup analyses revealed greater pCR differences in hormone receptor–positive disease (58.7% vs. 36.7%) and stage II disease (82.1% vs. 48.0%).
Following a median follow-up of 37.5 months, 3 event-free survival (EFS) events were observed in the PLD-based concurrent arm compared with 8 in the EC-based sequential arm (hazard ratio [HR] = 0.35; 95% CI, 0.09–1.32; P = 0.105). The estimated 3-year EFS rates were 96.0% (95% CI, 88.1–98.7) in the concurrent group and 90.7% (95% CI, 81.5–95.6) in the sequential group. Attaining pCR was significantly associated with improved EFS across the study population (HR = 0.15; 95% CI, 0.03–0.71; P = 0.006).
Assessment of cardiac safety revealed comparable profiles across both treatment arms, with no instances of symptomatic cardiac dysfunction and only one grade ≥3 cardiotoxicity event reported in the EC-based sequential arm. These findings support PLD-based concurrent therapy with trastuzumab and pertuzumab as an effective and safe neoadjuvant strategy in high-risk HER2-positive breast cancer, warranting further evaluation in phase III trials.
Key Takeaways
- Neoadjuvant concurrent pegylated liposomal doxorubicin plus trastuzumab and pertuzumab achieved a higher pathological complete response rate than sequential epirubicin and cyclophosphamide chemotherapy (67.5% vs. 48.7%; difference, 18.8%; 95% CI, 3.6–34.0; P = 0.033), with subgroups showing 58.7% versus 36.7% in hormone receptor–positive disease and 82.1% versus 48.0% in stage II disease.
- At a median follow-up of 37.5 months, the concurrent regimen showed an estimated 3-year event-free survival of 96.0% (95% CI, 88.1–98.7) versus 90.7% (95% CI, 81.5–95.6) for sequential therapy (HR = 0.35; 95% CI, 0.09–1.32; P = 0.105), while achieving pathological complete response was significantly associated with improved event-free survival (HR = 0.15; 95% CI, 0.03–0.71; P = 0.006).
- Cardiac safety was comparable between arms, characterized by an absence of symptomatic cardiac dysfunction and only one grade ≥3 cardiotoxicity event occurring in the sequential group.
Read the original sourceSignal Transduction and Targeted Therapy
